64091742PCR0002
Research type
Research Study
Full title
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer
IRAS ID
279686
Contact name
Vincent Khoo
Contact email
Sponsor organisation
Janssen-Cilag International NV
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 11 months, 20 days
Research summary
Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzymes are responsible for the repair of DNA single-strand breaks. PARP inhibitors (PARPi) inhibit this repair by blocking activity or trapping PARP on DNA. Previous research has shown that men with metastatic prostate cancer who have particular DNA-repair defects may be more sensitive to certain treatments. The purpose of this study is to further investigate DNA-repair defects to identify men who may potentially benefit from further therapeutic studies into these treatments, including PARPi.
This is a basic science study involving no change to participant’s clinical treatment. Following provision of informed consent, participants will be asked to provide a saliva sample for analysis. Participants will also be asked to allow researchers to analyse an existing tumour sample that will have been collected as part of routine care. This will be collected within 30 days of the study visit to provide the saliva sample. No further involvement or follow-up will be required of participants.
REC name
London - Fulham Research Ethics Committee
REC reference
20/LO/0430
Date of REC Opinion
31 Mar 2020
REC opinion
Favourable Opinion